ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS
|
|
- Anis Ramsey
- 5 years ago
- Views:
Transcription
1 ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM025D March 2016 Neha Maliwal Project Analyst ISBN: BCC Research 49 Walnut Park, Building 2 Wellesley, MA USA (toll-free within the USA), or (+1) information@bccresearch.com
2 TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2 STUDY GOALS AND OBJECTIVES 2 REASONS FOR DOING THE STUDY 2 SCOPE OF REPORT 3 INTENDED AUDIENCE 3 RESEARCH METHODOLOGY 4 ANALYST'S CREDENTIALS 5 RELATED BCC RESEARCH REPORTS 5 BCC RESEARCH WEBSITE 5 DISCLAIMER 5 CHAPTER 2 EXECUTIVE SUMMARY 7 SUMMARY TABLE GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ SUMMARY FIGURE GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 ($ 8 8 CHAPTER 3 MARKET OVERVIEW 10 INTRODUCTION 10 BACTERIA 10 TABLE 1 DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA 11 GRAM-POSITIVE BACTERIA 12 GRAM-NEGATIVE BACTERIA 12 Mycobacterium 13 TABLE 2 CLASSIFICATION OF BACTERIA BY SHAPE 13 BACTERIAL INFECTIONS 14 RESPIRATORY TRACT INFECTIONS 15 Upper Respiratory Tract Infection 15 TABLE 3 PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS 15 TABLE 4 INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) Lower Respiratory Tract Infection 17 PNEUMONIA 17 TABLE 5 COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED PNEUMONIA Community-acquired Pneumonia 18 Hospital-acquired Pneumonia 18 TABLE 6 PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING BACTERIAL PNEUMONIA TABLE 7 INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010 (NUMBER/%) TUBERCULOSIS 20 URINARY TRACT INFECTIONS (UTI) 20 TABLE 8 INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) SKIN AND SKIN STRUCTURE INFECTIONS
3 TABLE 9 INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) Cellulitis and Erysipelas 22 Folliculitis 22 Impetigo and Ecthyma 23 Abscesses 23 Carbuncles and Furuncles 23 GYNECOLOGICAL INFECTIONS 23 TABLE 10 INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) DEFINITION OF ANTIBIOTIC 24 CLASSIFICATION OF ANTIBIOTICS 24 FIGURE 1 CLASSIFICATION OF ANTIBIOTICS 25 HISTORY OF ANTIBIOTICS AND CURRENT STATUS 25 PRE-ANTIBIOTIC ERA 25 ANTIBIOTIC ERA 26 TABLE 11 U.S. LIFE EXPECTANCY AT BIRTH, (YEARS) 26 TABLE 12 ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES ANTIBIOTIC-RESISTANT BACTERIA 28 MECHANISM OF RESISTANCE 29 TABLE 13 ANTIBIOTICS: MODE OF ACTION 30 Mechanisms of Antimicrobial Resistance 30 TABLE 14 ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050 (NUMBER) Methods for the Dissemination of Antimicrobial Resistance Genes 32 Resistance to B-Lactam Antibiotics 32 Tetracycline Resistance 32 Chloramphenicol Resistance 32 Aminoglycoside Resistance 33 Quinolone Resistance 33 Macrolide, Lincosamide, and Streptogramin (MLS) Resistance 33 Glycopeptide Resistance 33 Sulfonamides and Trimethoprim Resistance 34 Multidrug Resistance 34 TABLE 15 TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE 34 TABLE 16 CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA 35 EMERGENCE OF POST-ANTIBIOTIC ERA 36 TABLE 17 BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE 37 FIGURE 2 CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT LEVEL TABLE 18 ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA BY REGION Limitation of Antibiotics 39 Some Antibiotics are Active against Only Certain Kinds of Bacteria Some Bacteria are Virulent and Can Kill Quickly 40 Some Bacteria Grow in Biofilms that cannot be Easily Penetrated by Antibiotics
4 DRIVERS RESTRAINTS AND OPPORTUNITIES 40 DRIVERS 40 Growth of the Global Pharmaceutical Market Driven by Antibiotics 40 Aging Population Propels the Growth of the Antibiotics Market 41 FIGURE 3 INCREASE IN AGING POPULATION, 2011 AND Public-Private Partnerships Encourage Antibiotic Development 42 Increasing Prevalence of Hospital-Acquired Infections Triggers Market Growth RESTRAINTS 43 Antibiotic Resistance 43 Declining R&D Investment Poses Long-Term Barrier to Market Growth 44 Genericization of Antibiotics Restrains Market Growth 44 OPPORTUNITIES 44 Market Expansion into Emerging Countries 44 Multidrug-Resistant Pathogens Provide an Opportunity to Develop Novel Antibacterial Agents BURNING ISSUE 46 New Antibiotic Discovered From Soil 46 MARKET SHARES OF KEY COMPANIES 46 FIGURE 4 GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%) 46 VALUE CHAIN OF ANTIBIOTICS 48 CHINA IS A BECOMING A CENTER FOR MICROBIAL THREATS 49 REGULATORY ISSUES 50 FDA AND INTERNATIONAL REGULATORY AGENCIES 50 RECENT REGULATORY REFORMS 51 KETEK CASE STUDY 51 KEY TRENDS AFFECTING THE MARKET 52 NEVER EVENTS 52 Impact on the Use of Antibiotics 53 FUNDING FOR NEW ANTIBIOTICS 53 United States 53 Infectious Diseases Society of America 53 NIH Funding 54 Public-Private Partnerships 54 Europe 55 Innovative Medicines Initiative 55 EMERGING DRUGS WITH NOVEL MECHANISMS OF ACTION 56 PharmaSea Project 56 Combination of Different Antibiotics 56 Others CHAPTER 4 ANTIBIOTIC RESEARCH AND DEVELOPMENT 59 REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH 59 FIGURE 5 REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH 60 LOW RETURN ON INVESTMENT 60 STRICT REGULATORY ENVIRONMENT 61 SCIENTIFIC CHALLENGES 62 STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH 62
5 FIGURE 6 STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH 62 PUSH STRATEGIES 63 Increasing Access to Research 63 Increasing the Number of Scientific Personnel 64 Direct Funding of Research 64 Translational Research 66 Tax Incentives 66 Product Development Partnerships 67 PULL STRATEGIES 67 Monetary Awards 67 Advance Market Commitments 68 Legal and Regulatory Initiatives 69 Clinical Trials 69 Accelerated Regulatory Review 70 Intellectual Property Rights Strategies 70 Increasing the Term of IP Protection and Data Exclusivity 71 Wildcard Patent Extension 71 Patent Buyouts 72 Pricing and Reimbursement 72 Other Legal/Regulatory Strategies 72 COMBINED PULL AND PUSH INCENTIVES 73 ORPHAN DRUG STATUS 73 TABLE 19 COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS Delinkage of Antibiotics 74 TABLE 20 LIST OF DELINKAGE MODELS 75 TABLE 21 LIST OF HYBRID MODELS CHAPTER 5 ANTIBIOTICS MARKET BY TYPE 80 MARKET SIZE ESTIMATION 80 MARKET SHARE ESTIMATION 80 GLOBAL ANTIBIOTICS MARKET BY CLASS 81 TABLE 22 GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ 81 TABLE 23 GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 ($ 81 FIGURE 7 ANTIBIOTICS BY CLASS 81 BETA-LACTAM ANTIBIOTICS 82 TABLE 24 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH 2020 ($ TABLE 25 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2020 ($ Extended Spectrum Beta-Lactamase 84 Metallo-Beta-Lactamases 85 FIGURE 8 TYPES OF BETA-LACTAM ANTIBIOTICS 85 Penicillins 85 TABLE 26 GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 ($ Types of Penicillin 87 TABLE 27 TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE
6 Cephalosporins 88 Side Effects 89 TABLE 28 GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 ($ Teflaro Driving the Cephalosporin Market 90 Generations of Cephalosporins 90 TABLE 29 GENERATIONS OF CEPHALOSPORIN 90 First-Generation Cephalosporins 91 TABLE 30 LIST OF FIRST-GENERATION CEPHALOSPORINS 91 Second-Generation Cephalosporins 92 TABLE 31 LIST OF SECOND-GENERATION CEPHALOSPORINS 92 Third-Generation Cephalosporins 92 Antipseudomonal Cephalosporins 93 TABLE 32 LIST OF THIRD-GENERATION CEPHALOSPORINS 93 Fourth-Generation Cephalosporins 94 TABLE 33 LIST OF FOURTH-GENERATION CEPHALOSPORINS 94 Fifth-Generation Cephalosporins 94 TABLE 34 LIST OF FIFTH-GENERATION CEPHALOSPORINS 95 Carbapenems 95 TABLE 35 GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 ($ TABLE 36 TYPES OF CARBAPENEMS 96 QUINOLONES AND FLUOROQUINOLONES 96 TABLE 37 DEVELOPMENT HISTORY OF FLUOROQUINOLONES 98 TABLE 38 GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH 2020 ($ TABLE 39 GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ Generations of Quinolones 99 First-Generation Quinolones 99 Second-Generation Fluoroquinolones 99 TABLE 40 GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ Third-Generation Fluoroquinolones 100 TABLE 41 GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ Levofloxacin: A Major Driver of the Market for Third-Generation Fluoroquinolones Fourth-Generation Fluoroquinolones 101 TABLE 42 GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020 ($ TABLE 43 TYPES OF QUINOLONES 102 TETRACYCLINE 103 TABLE 44 GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 ($ TABLE 45 TYPES OF TETRACYCLINE 104 MACROLIDES 105 TABLE 46 GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 ($
7 Ketolides 106 Ketek 107 TABLE 47 TYPES OF MACROLIDES/KETOLIDES 107 OTHER ANTIBIOTICS 107 Pseudomonas Aeruginosa 107 TABLE 48 GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 ($ 108 CHAPTER 6 VETERINARY ANTIBIOTICS MARKET 111 INTRODUCTION 111 TABLE 49 DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS 111 TABLE 50 GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2020 ($ VETERINARY APPLICATIONS 112 FEED APPLICATION 112 FDA to Phase out Antibiotics from Food Production 113 THERAPEUTIC APPLICATIONS 114 TABLE 51 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2020 ($ TABLE 52 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2020 ($ OTHER APPLICATIONS CHAPTER 7 COMPANY PROFILES 118 ASTRAZENECA 118 FINANCIALS 118 TABLE 53 ASTRAZENECA REVENUES AND R &D EXPENDITURES, ($ MILLIONS/%) DEVELOPMENTS 119 TABLE 54 ASTRAZENECA DEVELOPMENTS 119 BAYER HEALTHCARE AG 120 FINANCIALS 120 TABLE 55 BAYER REVENUES AND R &D EXPENDITURES, ($ MILLIONS/%) 120 DEVELOPMENTS 120 CUBIST PHARMACEUTICALS 120 DEVELOPMENTS 121 TABLE 56 CUBIST PHARMACEUTICAL DEVELOPMENTS 121 GLAXOSMITHKLINE 122 FINANCIALS 122 TABLE 57 GSK REVENUES AND R & D EXPENDITURES, ($ MILLIONS/%) 122 DEVELOPMENTS 123 TABLE 58 GSK DEVELOPMENTS 123 JOHNSON & JOHNSON 124 FINANCIALS 124 TABLE 59 JOHNSON & JOHNSON REVENUES AND R &D EXPENDITURES, ($ MILLIONS/%) DEVELOPMENTS 125 TABLE 60 JOHNSON & JOHNSON DEVELOPMENTS 125 MERCK & CO
8 FINANCIALS 125 TABLE 61 MERCK & CO. REVENUES AND R &D EXPENDITURES, ($ MILLIONS/%) DEVELOPMENTS 126 TABLE 62 MERCK & CO.DEVELOPMENTS 126 PFIZER 126 FINANCIALS 127 TABLE 63 PFIZER REVENUES AND R &D EXPENDITURES, ($ MILLIONS/%) 127 DEVELOPMENTS 127 TABLE 64 PFIZER DEVELOPMENTS 127 RECENT MERGERS AND ACQUISITIONS 128 TABLE 65 LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET CHAPTER 8 CLINICAL TRIALS ON ANTIBIOTICS 133 FIGURE 9 ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%) 134 TABLE 66 ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, ANTIBIOTICS IN PHASE II CLINICAL TRIALS 136 TABLE 67 ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, ANTIBIOTICS IN PHASE I CLINICAL TRIALS 137 TABLE 68 ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, TABLE 69 NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT REPRESENT NEW CHEMICAL CLASSES, CHAPTER 9 OVERVIEW OF BACTERIA TYPES 142 DISEASE ORGANISMS, DIAGNOSTICS, CLINICAL MANIFESTATIONS AND TREATMENTS TABLE 70 LIST OF GRAM-POSITIVE BACTERIA 142 TABLE 71 LIST OF GRAM-NEGATIVE BACTERIA 146 TABLE 72 LIST OF GRAM-NEGATIVE COCCI 151 TABLE 73 LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS TABLE 74 LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT 155 TABLE 75 LIST OF GRAM-NEGATIVE SPIROCHETES 159 TABLE 76 LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES 161 TABLE 77 LIST OF MISCELLANEOUS BACTERIA CHAPTER 10 LIST OF ACRONYMS 166 LIST OF ACRONYMS 166
9 LIST OF TABLES TABLE HEADING SUMMARY TABLE GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ TABLE 1 DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA 11 TABLE 2 CLASSIFICATION OF BACTERIA BY SHAPE 13 TABLE 3 PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS 15 TABLE 4 INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) TABLE 5 COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED PNEUMONIA TABLE 6 PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING BACTERIAL PNEUMONIA TABLE 7 INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010 (NUMBER/%) TABLE 8 INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) TABLE 9 INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) TABLE 10 INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%) TABLE 11 U.S. LIFE EXPECTANCY AT BIRTH, (YEARS) 26 TABLE 12 ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES TABLE 13 ANTIBIOTICS: MODE OF ACTION 30 TABLE 14 ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050 (NUMBER) TABLE 15 TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE 34 TABLE 16 CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA 35 TABLE 17 BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE 37 TABLE 18 ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA BY REGION TABLE 19 COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS 73 TABLE 20 LIST OF DELINKAGE MODELS 75 TABLE 21 LIST OF HYBRID MODELS 77 TABLE 22 GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 ($ 81 TABLE 23 GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 ($ 81 TABLE 24 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH 2020 ($ TABLE 25 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2020 ($ TABLE 26 GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 ($ TABLE 27 TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE 88 TABLE 28 GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 ($ TABLE 29 GENERATIONS OF CEPHALOSPORIN 90 TABLE 30 LIST OF FIRST-GENERATION CEPHALOSPORINS 91 TABLE 31 LIST OF SECOND-GENERATION CEPHALOSPORINS 92 TABLE 32 LIST OF THIRD-GENERATION CEPHALOSPORINS 93 TABLE 33 LIST OF FOURTH-GENERATION CEPHALOSPORINS
10 TABLE HEADING TABLE 34 LIST OF FIFTH-GENERATION CEPHALOSPORINS 95 TABLE 35 GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 ($ TABLE 36 TYPES OF CARBAPENEMS 96 TABLE 37 DEVELOPMENT HISTORY OF FLUOROQUINOLONES 98 TABLE 38 GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH 2020 ($ TABLE 39 GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ TABLE 40 GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ TABLE 41 GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 ($ TABLE 42 GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020 ($ TABLE 43 TYPES OF QUINOLONES 102 TABLE 44 GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 ($ TABLE 45 TYPES OF TETRACYCLINE 104 TABLE 46 GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 ($ TABLE 47 TYPES OF MACROLIDES/KETOLIDES 107 TABLE 48 GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 ($ TABLE 49 DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS 111 TABLE 50 GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2020 ($ TABLE 51 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2020 ($ TABLE 52 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2020 ($ TABLE 53 ASTRAZENECA REVENUES AND R &D EXPENDITURES, ($ MILLIONS/%) TABLE 54 ASTRAZENECA DEVELOPMENTS 119 TABLE 55 BAYER REVENUES AND R &D EXPENDITURES, ($ MILLIONS/%) 120 TABLE 56 CUBIST PHARMACEUTICAL DEVELOPMENTS 121 TABLE 57 GSK REVENUES AND R & D EXPENDITURES, ($ MILLIONS/%) 122 TABLE 58 GSK DEVELOPMENTS 123 TABLE 59 JOHNSON & JOHNSON REVENUES AND R &D EXPENDITURES, ($ MILLIONS/%) TABLE 60 JOHNSON & JOHNSON DEVELOPMENTS 125 TABLE 61 MERCK & CO. REVENUES AND R &D EXPENDITURES, ($ MILLIONS/%) TABLE 62 MERCK & CO.DEVELOPMENTS 126 TABLE 63 PFIZER REVENUES AND R &D EXPENDITURES, ($ MILLIONS/%) 127 TABLE 64 PFIZER DEVELOPMENTS 127 TABLE 65 LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET 129 TABLE 66 ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, TABLE 67 ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, TABLE 68 ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS,
11 TABLE HEADING TABLE 69 NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT REPRESENT NEW CHEMICAL CLASSES, 2015 TABLE 70 LIST OF GRAM-POSITIVE BACTERIA 142 TABLE 71 LIST OF GRAM-NEGATIVE BACTERIA 146 TABLE 72 LIST OF GRAM-NEGATIVE COCCI 151 TABLE 73 LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS TABLE 74 LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT 155 TABLE 75 LIST OF GRAM-NEGATIVE SPIROCHETES 159 TABLE 76 LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES 161 TABLE 77 LIST OF MISCELLANEOUS BACTERIA
12 LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 ($ FIGURE 1 CLASSIFICATION OF ANTIBIOTICS 25 FIGURE 2 CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT LEVEL FIGURE 3 INCREASE IN AGING POPULATION, 2011 AND FIGURE 4 GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%) 46 FIGURE 5 REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH 60 FIGURE 6 STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH 62 FIGURE 7 ANTIBIOTICS BY CLASS 81 FIGURE 8 TYPES OF BETA-LACTAM ANTIBIOTICS 85 FIGURE 9 ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%)
Summary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite
More informationAntimicrobial Resistance Initiative
Antimicrobial Resistance Initiative Antimicrobial Resistance Initiative Resistance to antimicrobial agents has become a threat to public health all over the world. Microorganisms become resistant to antimicrobial
More informationEU Research on Antimicrobial drug resistance Anna Lönnroth Sjödén Unit Infectious Diseases, Directorate Health DG Research European Commission
1 EU Research on Antimicrobial drug resistance Anna Lönnroth Sjödén Unit Infectious Diseases, Directorate Health DG Research European Commission PathoGenomics ERA-NET, Brussels, 23 September 2010 2 EU
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union November 2012 Highlights on antibiotic consumption Antibiotic use is one of the main factors responsible for the development and
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationDR. BASHIRU BOI KIKIMOTO
OVERVIEW OF ANTIMICROBIAL RESISTANCE AND ANTIMICROBIAL USE IN GHANA PRESENTED BY : DR. BASHIRU BOI KIKIMOTO DVM. PhD VETERINARY PUBLIC HEALTH HEAD - PUBLIC HEALTH UNIT & FOOD SAFETY UNIT VENUE: SWATZILAND
More informationCommercial Challenges: Perspectives from Big Pharma
Commercial Challenges: Perspectives from Big Pharma John H. Rex, MD Vice President Clinical Infection AstraZeneca 1 Disclaimers The following are my views and not necessarily those of my employer, AstraZeneca,
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationEpidemiology and Economics of Antibiotic Resistance
Epidemiology and Economics of Antibiotic Resistance Eili Y. Klein February 17, 2016 Health Watch USA Meeting I. The burden of antibiotic resistance is a growing global threat, but hard numbers are lacking
More informationUSA ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA
FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationMike Apley Kansas State University
Mike Apley Kansas State University 2003 - Daptomycin cyclic lipopeptides 2000 - Linezolid - oxazolidinones 1985 Imipenem - carbapenems 1978 - Norfloxacin - fluoroquinolones 1970 Cephalexin - cephalosporins
More informationHow is Ireland performing on antibiotic prescribing?
European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical
More informationHealthcare Facilities and Healthcare Professionals. Public
Document Title: DOH Guidelines for Antimicrobial Stewardship Programs Document Ref. Number: DOH/ASP/GL/1.0 Version: 1.0 Approval Date: 13/12/2017 Effective Date: 14/12/2017 Document Owner: Applies to:
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationWHO perspective on antimicrobial resistance
WHO perspective on antimicrobial resistance Bernadette Abela-Ridder, DVM, MSc, PhD Global Foodborne Infections Network (GFN) Coordinator Department of Food Safety and Zoonoses (FOS) 1 Overview of presentation
More informationImagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening
Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be
More informationEC Workshop on scientific advice from AMEG
EC Workshop on scientific advice from AMEG Brussels, 26 Nov 2015 Session 2: Antibiotic Categorisation AMEG Q2 Karolina Törneke / Helen Jukes Liability disclaimer: The views or positions expressed in this
More informationReport on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli"
Preserving the Power of Antibiotics Report on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli" Held on Thursday, September 30, 2004 in Boston, MA Preceding
More informationQuelle politique antibiotique pour l Europe? Dominique L. Monnet
Quelle politique antibiotique pour l Europe? Dominique L. Monnet National Center for Antimicrobials & Infection Control Statens Serum Institut, Copenhagen, Denmark Opinion of the Section for Protection
More informationAntibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance
More informationEuropean Medicines Agency role and experience on antimicrobial resistance
European Medicines Agency role and experience on antimicrobial resistance Regional Training Workshop on Antimicrobial Resistance (AMR) Responding to the global challenge of AMR threats: toward a one health
More informationHuman health impacts of antibiotic use in animal agriculture
Human health impacts of antibiotic use in animal agriculture Beliefs, opinions, and evidence Peter Davies BVSc, PhD College of Veterinary Medicine, University of Minnesota, USA Terminology Antibiotic Compound
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationWhat is the problem? Latest data on antibiotic resistance
European Antibiotic Awareness Day 2009 What is the problem? Latest data on antibiotic resistance Zsuzsanna Jakab, ECDC Director Launch Seminar for EAAD Stockholm, 18 November 2009 Fluoroquinolone-resistant
More informationIntroduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018
Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.
More informationNorwegian policies to address antimicrobial resistance
Norwegian policies to address antimicrobial resistance Frode Forland, Specialist Director, Division of Infectious Control and Environmental Health, Norwegian Institute of Public Health Karianne Johansen,
More informationA Conversation with Dr. Steve Solomon and Dr. Jean Patel on Antimicrobial Resistance June 18 th, 2013
A Conversation with Dr. Steve Solomon and Dr. Jean Patel on Antimicrobial Resistance June 18 th, 2013 Participant List Dr. Steve Solomon, Director, Office of Antimicrobial Resistance, Division of Healthcare
More informationReinvigorating the Oral Antibacterial Drug Development Pipeline
Reinvigorating the Oral Antibacterial Drug Development Pipeline November 20, 2014 Discussion Guide Introduction Antibacterial drugs are a critical component of the nation s public health armamentarium
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationWHO efforts to reduce the impact on public and animal health of antibiotic use in animals. Dr Danilo Lo Fo Wong Senior Adviser AMR
WHO efforts to reduce the impact on public and animal health of antibiotic use in animals Dr Danilo Lo Fo Wong Senior Adviser AMR Antimicrobial resistance (AMR): a public and animal health issue Widespread
More informationAntimicrobial Stewardship in Ambulatory Care
Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationPosition Statement. Responsible Use of Antibiotics in the Australian Chicken Meat Industry. 22 February What s the Issue?
22 February 2018 Position Statement Responsible Use of Antibiotics in the Australian Chicken Meat Industry What s the Issue? Antimicrobial resistance (AMR) The use of antibiotics in both humans and animals
More informationGlobal Overview on Antibiotic Use Policies in Veterinary Medicine
Global Overview on Antibiotic Use Policies in Veterinary Medicine Dr Shabbir Simjee Global Regulatory & Technical Advisor Microbiology & Antimicrobials Elanco Animal Health Basingstoke, England simjeess@elanco.com
More informationDr. P. P. Doke. M.D., D.N.B., Ph.D., FIPHA. Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune
Dr. P. P. Doke M.D., D.N.B., Ph.D., FIPHA Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune 1 Anti microbial resistance is now a global geometrically increasing threat
More informationREPORT ON THE ANTIMICROBIAL RESISTANCE (AMR) SUMMIT
1 REPORT ON THE ANTIMICROBIAL RESISTANCE (AMR) SUMMIT The Department of Health organised a summit on Antimicrobial Resistance (AMR) the purpose of which was to bring together all stakeholders involved
More information1 January 2017, It is Coming Preparation for VFD Changes Beginning 1 January 2017
1 January 2017, It is Coming Preparation for VFD Changes Beginning 1 January 2017 ASM-00007 1 CHAPTERS Background: Food and Drug Administration (FDA) guidance documents Introduction: Veterinary Feed Directive
More informationImpact of NHS England Quality Indicators on Antimicrobial Resistance. Professor Alan Johnson National Infection Service Public Health England
Impact of NHS England Quality Indicators on Antimicrobial Resistance Professor Alan Johnson National Infection Service Public Health England A Risk Assessment of Antibiotic Pan-Drug Resistance in the UK:
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationAntimicrobial Use and Antimicrobial Resistance in Relation to the Canadian Pork Sector Presented by Jorge Correa Pork Committee Banff May 2013
Antimicrobial Use and Antimicrobial Resistance in Relation to the Canadian Pork Sector Presented by Jorge Correa Pork Committee Banff May 2013 Part of the Slides were extracted from a Paul Dick presentation
More informationInhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology Zeina Alkudmani Chemotherapy Definitions The use of any chemical (drug) to treat any disease or condition. Chemotherapeutic Agent Any drug
More informationAntimicrobial Resistance: Urgent Need for Responsible and Sustainable R&D Incentives Support HR 6294: REVAMP Act of 2018
Antimicrobial Resistance: Urgent Need for Responsible and Sustainable R&D Incentives Support HR 6294: REVAMP Act of 2018 Consensus AMR is a Critical Public Health Threat requiring immediate and significant
More informationAntibiotic Stewardship in the LTC Setting
Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationAntimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationThe UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England
The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England Chief Medical Officer - Annual Report 2013 Antimicrobial resistance poses catastrophic
More informationAntimicrobial agents. are chemicals active against microorganisms
Antimicrobial agents are chemicals active against microorganisms Antibacterial Agents Are chemicals active against bacteria Antimicrobials Antibacterial Antifungal Antiviral Antiparasitic: -anti protozoan
More informationAntimicrobial Resistance and Prescribing
Antimicrobial Resistance and Prescribing John Ferguson, Microbiology & Infectious Diseases, John Hunter Hospital, University of Newcastle, NSW, Australia M Med Part 1 updates UPNG 2017 Tw @mdjkf http://idmic.net
More informationAnimal Health and Antibiotics Looking Ahead with Science
Animal Health and Antibiotics Looking Ahead with Science t The Overton Window Unthinkable Radical Acceptable Sensible Popular Policy Prohibition of therapeutic uses of medically important antimicrobials
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationAn#bio#cs and challenges in the wake of superbugs
An#bio#cs and challenges in the wake of superbugs www.biochemj.org/bj/330/0581/bj3300581.htm ciss.blog.olemiss.edu Dr. Vassie Ware Bioscience in the 21 st Century November 14, 2014 Who said this and what
More informationAntibiotic Stewardship in Human Health- Progress and Opportunities
National Center for Emerging and Zoonotic Infectious Diseases Antibiotic Stewardship in Human Health- Progress and Opportunities CAPT Lauri A. Hicks, D.O. Director, Office of Antibiotic Stewardship Division
More informationCommunity-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018
Community-Associated C. difficile Infection: Think Outside the Hospital Maria Bye, MPH Epidemiologist Maria.Bye@state.mn.us 651-201-4085 May 1, 2018 Clostridium difficile Clostridium difficile Clostridium
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationEnterobacter aerogenes
Enterobacter aerogenes Enterobacter sp. Enterobacter sp. Species: Enterobacter aerogenes Enterobacter agglomerans Enterobacter cloacae causes UTI, enterotoxigenic Often found in the normal intestinal flora,
More informationObjective 1/20/2016. Expanding Antimicrobial Stewardship into the Outpatient Setting. Disclosure Statement of Financial Interest
Expanding Antimicrobial Stewardship into the Outpatient Setting Michael E. Klepser, Pharm.D., FCCP Professor Pharmacy Practice Ferris State University College of Pharmacy Disclosure Statement of Financial
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationDRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION. Cara Wilder Ph.D. Technical Writer March 13 th 2014
DRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION Cara Wilder Ph.D. Technical Writer March 13 th 2014 ATCC Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas,
More informationAntibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University
Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine Mike Apley Kansas State University Changes in Food Animal Antibiotic Use How the uses of antibiotics in
More informationAntimicrobial stewardship in companion animals: Welcome to a whole new era
Antimicrobial stewardship in companion animals: Welcome to a whole new era John F. Prescott, University Professor Emeritus, Department of Pathobiology, University of Guelph, Guelph, Ontario NG 2W1 prescott@uoguelph.ca
More informationAntimicrobial use in poultry: Emerging public health problem
Antimicrobial use in poultry: Emerging public health problem Eric S. Mitema, BVM, MS, PhD CPD- Diagnosis and Treatment of Poultry Diseases FVM, CAVS, 6 th. August, 2014 AMR cont Antibiotics - Natural or
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationDr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health
Dr Elisabeth Erlacher Vindel Head of Science and New Technologies Departement OIE AMR strategy and activities related to animal health Regional Workshop for National Focal Points for Veterinary Products
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationOIE List of Antimicrobial Agents of Veterinary Importance and OIE Standards and Activities
Veterinary Importance and OIE Standards and Activities Consultation meeting with stakeholders - Request from the European Commission for advice on the impact on public and animal health of the use of antibiotics
More informationThe South African AMR strategy. 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa
The South African AMR strategy 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa Background to AMR 2 What is Antimicrobial stewardship and
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
More informationCombating Antimicrobial Resistance: The Way Forward
Combating Antimicrobial Resistance: The Way Forward James M. Hughes, MD Professor of Medicine and Public Health Emory University Atlanta, GA NIAA Antibiotic Symposium November 14, 2014 Disclosure No conflicts
More information2016/LSIF/FOR/004 Policies to Promote Patient Access to Innovative Treatments and Combat Antimicrobial Resistance
2016/LSIF/FOR/004 Policies to Promote Patient Access to Innovative Treatments and Combat Antimicrobial Resistance Submitted by: Merck Sharp & Dohme Policy Forum on Strengthening Surveillance and Laboratory
More informationProtocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland
Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Version 1.0 23 December 2011 General enquiries and contact details This is the first version (1.0) of the Protocol
More informationGeneral Infectious Disease Concepts/Resources
General Infectious Disease Concepts/Resources Learning Objectives: 1. Distinguish between foundational infectious disease concepts including gram positive and negative bacteria, bacteriostatic and bactericidal
More informationPharm 262: Antibiotics. 1 Pharmaceutical Microbiology II DR. C. AGYARE
Pharm 262: 1 Pharmaceutical Microbiology II Antibiotics DR. C. AGYARE Reference Books 2 HUGO, W.B., RUSSELL, A.D. Pharmaceutical Microbiology. 6 th Ed. Malden, MA: Blackwell Science, 1998. WALSH, G. Biopharmaceuticals:
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationANTIMICROBIAL STEWARDSHIP: ADVANCING PATIENT CARE BY IMPROVING MEDICATION USE
ANTIMICROBIAL STEWARDSHIP: ADVANCING PATIENT CARE BY IMPROVING MEDICATION USE ANTHONY M. CASAPAO, PHARM.D. ASSISTANT PROFESSOR OF PHARMACY PRACTICE HUSSON UNIVERSITY SCHOOL OF PHARMACY CLINICAL INFECTIOUS
More informationrunning head: SUPERBUGS Humphreys 1
running head: SUPERBUGS Humphreys 1 Superbugs GCH 360 Term Paper Assignment Kelly Humphreys April 30, 2014 SUPERBUGS Humphreys 2 Introduction The World Health Organization (WHO) recognizes antibiotic resistance
More informationANTIBIOTIC RESISTANCE. Syed Ziaur Rahman, MD, PhD D/O Pharmacology, JNMC, AMU, Aligarh
ANTIBIOTIC RESISTANCE Syed Ziaur Rahman, MD, PhD D/O Pharmacology, JNMC, AMU, Aligarh WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development
More informationEvaluation of EU strategy to combat AMR
Evaluation of EU strategy to combat AMR Advisory Group of the Food Chain 30 April 2015 Martial Plantady Legislative officer DDG2.G4: Food, Alert Systems & Training DG Health and Food Safety Antimicrobial
More informationMicrobiology : antimicrobial drugs. Sheet 11. Ali abualhija
Microbiology : antimicrobial drugs Sheet 11 Ali abualhija return to our topic antimicrobial drugs, we have finished major group of antimicrobial drugs which associated with inhibition of protein synthesis
More informationDevelopment and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics
Priority Topic B Diagnostics Development and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics The overarching goal of this priority topic is to stimulate the design,
More informationChapter 51. Clinical Use of Antimicrobial Agents
Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationOverview of antibiotic combination issues.
Overview of antibiotic combination issues. Professor Anthony Coates St George s, University of London Founder, CSO, Helperby Therapeutics Ltd The most serious problem is Carbapenem resistant Gram-negatives
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationOIE initiative establishing a global database on consumption of antimicrobials for animals: state of play
OIE initiative establishing a global database on consumption of antimicrobials for animals: state of play European Surveillance of Veterinary Antimicrobial Consumption stakeholders meeting, London, UK,
More informationNovel advances in MDR treatment. TO WIN, STOP FIGHTING By:
Novel advances in MDR treatment. TO WIN, STOP FIGHTING By: Dr. Boris Farber Dr. Ilya Kleyn Introduction NOIGEL LLC is a New York based company that was established in 2010. Our mission is to find new innovative
More informationThe challenge of growing resistance
EXECUTIVE SUMMARY Around 2.4 million people could die in Europe, North America and Australia between 2015-2050 due to superbug infections unless more is done to stem antibiotic resistance. However, three
More informationHosted by Dr. Benedetta Allegranzi, WHO Patient Safety Agency A Webber Training Teleclass
The History of Medicine Antimicrobial Resistance Issues Worldwide and the WHO Approach to Combat It Carmem Lúcia Pessoa-Silva, MD, PhD Health Security and Environment Cluster, WHO HQ, Geneva Hosted by
More informationMicrobiology ( Bacteriology) sheet # 7
Microbiology ( Bacteriology) sheet # 7 Revision of last lecture : Each type of antimicrobial drug normally targets a specific structure or component of the bacterial cell eg:( cell wall, cell membrane,
More information